13F Pro Quality Score

27.2/100

Rank #2,593 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

12.7/100

Profitability

17.4/100

Balance Sheet

15.6/100

Earnings Quality

47.6/100

Free Cash Flow

22.6/100

Institutional Flow

42.3/100

Revenue Scale

37.5/100

Dilution Risk

52.7/100
Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

NOTV Stock Analysis & AI Quality Score

Data updated 2026-08-29

AI stock analysis and institutional research for Inotiv, Inc. (NOTV), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NOTV at 27.2/100 on a 32-signal composite quality model, placing it at rank #2,593 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (12.7) and balance sheet strength (15.6), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q1 2026), Inotiv, Inc. reports quarterly revenue of $117.7M, net income of $-32.5M, free cash flow of $-3.2M. Top institutional holders of NOTV by reported 13-F value include Orgel Wealth Management, BANK OF AMERICA, LPL Financial, based on the most recent SEC filings. NOTV trades on the Nasdaq exchange and files with the SEC under CIK 720154. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NOTV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inotiv, Inc. directly from SEC EDGAR. Inotiv, Inc.'s 13F Pro composite quality score has ranged between 21 and 50 since 2021, currently 27.2 — a declining long-term trajectory across 66 quarterly and live scoring snapshots.

Fun facts about Inotiv, Inc.

Quirks, history, and lore behind NOTV — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in Indiana.
  • 2
    The Numbers
    Annual revenue in the range of a few hundred million dollars, built largely through acquisitions that roughly tripled its size in a short stretch — growth that came with a hefty debt load.
  • 3
    The History
    Rooted in pharmaceutical research services dating back decades, the company rebranded and relisted as it pivoted from a niche university-affiliated lab into a full-service contract research organization.
  • 4
    The Secret
    Its core business is running preclinical studies on behalf of drug developers — meaning it tests compounds in animals and lab settings so its clients don't have to build that infrastructure themselves.
  • 5
    The Lore
    A splashy acquisition of Envigo dramatically expanded its research model supply operations, making it one of the larger providers of laboratory animals in North America — and drawing intense scrutiny from regulators and activists alike.
  • 6
    The Giveaway
    This contract research and preclinical services company, trading under a four-letter ticker on Nasdaq, faced an FDA consent decree tied to its animal research facilities after the Envigo deal put it under a microscope.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$117.7M

Net Income

Q1 2026

$-32.5M

Free Cash Flow

Q1 2026

$-3.2M

ROIC

Q1 2026

-8.6%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+4.5% YoY
$513.0MFY 2025
FY22 $547.7MFY23 $572.4MFY24 $490.7MFY25 $513.0M

Net Income

+36.7% YoY
$-68.6MFY 2025
FY22 $-337.0MFY23 $-105.1MFY24 $-108.4MFY25 $-68.6M

Operating Income

+64.2% YoY
$-30.9MFY 2025
FY22 $-263.5MFY23 $-81.5MFY24 $-86.4MFY25 $-30.9M

EPS (Diluted)

+49.6% YoY
$-2.11FY 2025
FY22 $-13.84FY23 $-4.10FY24 $-4.19FY25 $-2.11

Total Assets

-1.3% YoY
$771.1MFY 2025
FY22 $962.9MFY23 $856.5MFY24 $781.4MFY25 $771.1M

Total Debt

+102.6% YoY
$804.2MFY 2025
FY22 $358.6MFY23 $385.7MFY24 $396.9MFY25 $804.2M

Op. Cash Flow

-53.6% YoY
$-10.5MFY 2025
FY22 $-5.2MFY23 $27.9MFY24 $-6.8MFY25 $-10.5M

Free Cash Flow

+7.0% YoY
$-27.1MFY 2025
FY22 $-41.5MFY23 $380.0KFY24 $-29.1MFY25 $-27.1M

Get alerted when NOTV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Inotiv, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of NOTV

Companies Similar to NOTV

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

CGC

Canopy Growth Corp

24
AI score
Similar quality profile · 2 shared holders
AVNS

AVANOS MEDICAL, INC.

36
AI score
Similar quality profile · 2 shared holders
BNR

Burning Rock Biotech Ltd

27
AI score
Similar quality profile
INGN

Inogen Inc

33
AI score
Similar quality profile
USNA

USANA HEALTH SCIENCES INC

40
AI score
Similar quality profile · 2 shared holders
OPK

OPKO HEALTH, INC.

22
AI score
Similar quality profile · 3 shared holders
ORGO

Organogenesis Holdings Inc.

30
AI score
Similar quality profile · 2 shared holders
TLRY

Tilray Brands, Inc.

28
AI score
Similar quality profile · 1 shared holders

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put NOTV on your watchlist

Track score changes the day Inotiv, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is NOTV a good stock to buy?

13F Pro's AI-powered analysis of Inotiv, Inc. (NOTV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NOTV are available on the NOTV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NOTV is classified as a small company.

Which hedge funds own NOTV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NOTV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Inotiv, Inc.'s investment landscape.